| 1.81 -0.18 (-9.05%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.53 |
1-year : | 2.87 |
| Resists | First : | 2.16 |
Second : | 2.46 |
| Pivot price | 2.06 |
|||
| Supports | First : | 1.7 |
Second : | 1.41 |
| MAs | MA(5) : | 1.99 |
MA(20) : | 2.06 |
| MA(100) : | 2.09 |
MA(250) : | 2.99 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 17.4 |
D(3) : | 24.2 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 5.5 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GDTC ] has closed below the lower bollinger band by 9.1%. Bollinger Bands are 40% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.96 - 1.98 | 1.98 - 1.99 |
| Low: | 1.67 - 1.68 | 1.68 - 1.7 |
| Close: | 1.79 - 1.81 | 1.81 - 1.83 |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Thu, 25 Jul 2024
CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2% - Defense World
Wed, 17 Jul 2024
CytoMed (GDTC): Pre-Market Stock Surge Amid Strategic Moves - Stocks Telegraph
Mon, 29 Jan 2024
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance
Tue, 23 Jan 2024
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 69.2 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 39 (K) |
| Shares Short P.Month | 35 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.98 |
| Profit Margin | 0 % |
| Operating Margin | -811.3 % |
| Return on Assets (ttm) | -27.3 % |
| Return on Equity (ttm) | -69.9 % |
| Qtrly Rev. Growth | -22.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -6.25 |
| PEG Ratio | 0 |
| Price to Book value | 1.84 |
| Price to Sales | 41.13 |
| Price to Cash Flow | -6.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|